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Radiation esophagitis (RE) is a common adverse event associated with radiotherapy for non–small cell lung cancer (NSCLC).
While plasmacytokine levels havebeencorrelatedwith other formsof radiation-induced toxicity, their associationwithREhas
been lesswell studied.We analyzed data from126 patients treated on 4 prospective clinical trials. Logistic regressionmodels
based on combinations of dosimetric factors [maximumdose to 2 cubic cm (D2cc) and generalized equivalent uniform dose
(gEUD)], clinical variables, and pretreatment plasma levels of 30 cytokineswere developed. Cross-validated estimates of area
under the receiver operating characteristic curve (AUC) and log likelihoodwere used to assess prediction accuracy. Dose-only
models predicted grade 3 RE with AUC values of 0.750 (D2cc) and 0.727 (gEUD). Combining clinical factors with D2cc
increased theAUC to0.779. Incorporating pretreatment cytokinemeasurements,modeled asdirect associationswithREand
as potential interactions with the dose-esophagitis association, produced AUC values of 0.758 and 0.773, respectively. D2cc
and gEUD correlated with grade 3 RE with odds ratios (ORs) of 1.094/Gy and 1.096/Gy, respectively. Female gender was
associated with a higher risk of RE, with ORs of 1.09 and 1.112 in the D2cc and gEUDmodels, respectively. Older age was
associated with decreased risk of RE, with ORs of 0.992/year and 0.991/year in the D2cc and gEUD models, respectively.
Combining clinical with dosimetric factors but not pretreatment cytokine levels yielded improved prediction of grade 3 RE
compared topredictionbydosealone.Suchmultifactorialmodelingmayproveuseful indirecting radiation treatmentplanning.
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Locally advanced non–small cell lung cancer (NSCLC) is often
treated with concurrent chemotherapy and radiation [1,2]. Radiation
esophagitis (RE) is a common complication of this treatment, with
the incidence of grade 3 or greater symptoms having been reported to
be as high as 25% in prospective trials [3]. Grade 3 esophagitis, per
Common Terminology Criteria for Adverse Events, indicates severe
symptoms requiring intervention such as tube feeding or parenteral
Translational Oncology Vol. 11, No. 1, 2018 Prediction of Radiation Esophagitis in NSCLC Hawkins et al. 103nutrition [4]. Acute RE usually develops between 2 and 4 weeks of
treatment and, in addition to affecting quality of life, can necessitate
treatment break, which is associated with inferior outcomes [5–7].
With improved understanding of the clinical, dosimetric, and
biologic risk factors for RE, it may be possible to identify patients
for whom stricter esophageal dose constraints, prophylactic nutritional
optimization, or other actionmay be beneficial for reducing toxicity and
increasing chances for completing treatment.
Clinical factors associated with RE include concurrent chemother-
apy, gender, age, body mass index, pretreatment dysphagia, and nodal
stage [8–10]. Dose-escalated, twice-daily, and hyopfractionated
radiotherapy courses increase risk [2,9,11–13]. Improved esophageal
sparing with intensity-modulated radiotherapy (IMRT) has shown
promise for reducing rates of grade 3+ RE compared to 3D-conformal
(3DCRT), although this has not been consistent in all studies
[14–22]. A multitude of dosimetric factors predictive of RE have been
described, including mean esophageal dose, maximum esophageal
dose, and various doses to esophageal surface area, length, and volumes
(including total, infield, and relative volumes) [8–10,14,23–39]. More
advanced approaches, including normal tissue complication probability
modeling and anatomic correction, have shown unclear benefit
[27,38,40]. More recently, a multi-institutional study evaluating
multiple dose-volume metrics identified the maximum dose to
2 cubic cm (D2cc) and generalized equivalent uniform dose (gEUD)
as superior parameters [41].
Cytokines represent a large, heterogeneous group of proteins
involved in regulating inflammatory and fibrotic responses to injury
[42]. Multiple cytokines have been linked with reflux-associated and
eosinophilic esophagitis [43–45]. Single nucleotide polymorphisms
(SNPs) in several cytokines and cytokine receptors have been
associated with an increased risk of RE [46–48]. In mouse models,
esophageal radiation has been found to induce transcription of
multiple inflammatory cytokines [49,50].
While plasma cytokine levels have been extensively investigated as
potential biomarkers for radiation-induced lung toxicity (RILT)
(reviewed in [51]), their potential role in RE has been less well
studied. In predicting RILT, differences in both pretreatment and
radiation-induced plasma cytokine levels have been shown to
correlate with risk [51–53]. However, as RE, compared to radiation
pneumonitis and pulmonary fibrosis, often develops relatively early in
radiation course, biomarkers evaluable prior to initiation of
radiotherapy would be of greatest utility for RE, as they could direct
intervention prior to the onset of toxicity. We hypothesized that
variations in pretreatment plasma cytokine levels may correlate with
increased or decreased risk of RE. We investigated combining
pretreatment plasma cytokine data with dosimetric and clinical factors
in an effort to improve prediction of RE in patients undergoing
definitive radiotherapy for NSCLC. Dosimetric factors of D2cc and
gEUD were selected due to recently published favorable results using
these parameters [41].
Materials and Methods
Study Population
This work analyzed data from 4 prospective Institutional Review
Board–approved lung-cancer studies: 1) a phase 1/2 study of radiation
dose escalation with concurrent chemotherapy, 2-3) two consecutive
studies using functional imaging and biomarkers to assess patient
outcome, and 4) a study using midtreatment positron emissiontomography (PET) to guide individualized dose escalation. Included
in this analysis were patients with stage I to III NSCLC treated with
standard fractionation, i.e., not stereotactic body radiotherapy. All
clinical data were prospectively collected. Smoking status was missing
for 10 patients, which was handled via single imputation.
Treatment Regimen
All patients were treated with definitive radiotherapy with or
without sequential or concurrent chemotherapy. In cases of sequential
treatment, chemotherapy was administered following radiotherapy.
In most cases, radiation was delivered using 3DCRT as previously
described [54], whereas IMRT was used for a minority of patients.
Gross tumor volume included the primary tumor and any involved
hilar or mediastinal lymph nodes, as determined by tissue diagnosis
and/or PET–computed tomography (CT). Uninvolved lymph node
regions were not included in the clinical target volume. The
esophagus was contoured per Radiation Therapy Oncology Group
guidelines on each patient's CT simulation scan. Tissue inhomogeneity
corrections were applied for all plans.
As dose and fractionation varied among patients, we standardized
values to biologic effective dose (BED), which normalizes doses of
various fractionations by supposing a hypothetical condition of an
infinite number of fractions. Tumor and esophageal BEDs were
calculated using the linear-quadratic formula using an alpha/beta ratio
of 10 Gy. Patients were evaluated weekly during radiotherapy and at
regular intervals following completion of treatment. Radiation-induced
esophageal toxicity was graded by physicians during on-treatment
and follow-up visits per Common Terminology Criteria for Adverse
Events v3.0 [4].
Cytokine Analysis
Plasma concentrations of 30 cytokines were measured: epidermal
growth factor, eotaxin, fractalkine, granulocyte colony stimulating
factor, granulocyte macrophage colony stimulating factor, interferon
α, interleukin (IL)1α, IL1β, IL2, IL4, IL5, IL6, IL7, IL8, IL10, IL12
subunit 40 (IL12p40), IL12 p35 and p40 heterodimer (IL12p70),
IL13, IL15, IL17, IL1 receptor antagonist, monocyte chemoattrac-
tant protein 1, macrophage inflammatory protein 1α, macrophage
inflammatory protein 1β, soluble CD40 ligand, TGFα, TGFβ1,
TNFα, and vascular endothelial growth factor. This panel was
selected to represent a diverse collection of cytokines implicated in
many inflammatory processes including RILT and esophagitis of
various etiologies. Cytokine measurements were performed in
platelet-poor plasma samples within 2 weeks prior to the start of
RT. Plasma samples were collected and prepared as previously
described [55]. Briefly, blood samples were collected in the presence
of the anticoagulant K2EDTA (dikalium salt of ethylenediaminetet-
raacetic acid) and placed on ice immediately after collection. Samples
were centrifuged within 2 hours of collection, after which the upper
one-third of the supernatants was collected and stored at −80°C. Prior
to cytokine measurements, samples were recentifuged in order to
generate platelet-poor samples for analysis. TGFβ1 levels were
measured using enzyme-linked immunosorbent assay as previously
described [53], while the other 29 cytokines were measured using
luminex multiplex assay (xMAP plasma assay; Luminx, St. Charles,
MO). All sample tests were run in duplicate. Some cytokine
measurements fell below a lower limit of detection. We used an ad hoc
methodology to detect and account for these censored measurements,
which is described in the Supplement.
Table 1. Patient Characteristics
Cohort with
Pretreatment Cytokine
Data (n = 126)
Full Cohort (n = 147)
Grade 3 esophagitis, # (%) 13 (10.3%) 15 (10.5%)
Esophageal dose, D2cc
Median (IQR) 62.7 Gy (56.1, 69.6) 62.1 Gy (56.0, 68.5)
# Missing n = 17 n = 22
Esophageal dose, gEUD
Median (IQR) 46.9 Gy (39.0, 51.8) 46.8 Gy (39.0, 51.7)
# Missing n = 17 n = 22
Target dose, BED
Median (IQR) 84.0 Gy (78.0, 93.6) 84.0 Gy (78.0, 94.4)
# Missing n = 3 n = 6
Sex, # (%)
Female 28 (22.2%) 33 (22.4%)
Age, year
Median (IQR) 65.8 (59.3, 73.4) 65.6 (59.3, 73.2)
Race/ethnicity, # (%)
Caucasian 121 (97.6%) 140 (97.2%)
African American 2 (1.6%) 3 (2.1%)
Asian 1 (0.8%) 1 (0.7%)
Not reported 2 3
KPS
Median (IQR) 87.5 (80, 90) 90 (80, 90)
Smoking status, # (%)
Former 57 (48.8%) 71 (51.8%)
Current 57 (48.8%) 62 (45.3%)
Never smoker 3 (2.6%) 4 (2.9%)
Not reported 9 10
Simple stage, # (%)
I 14 (11.1%) 15 (10.2%)
II 14 (11.1%) 17 (11.6%)
III 98 (77.8%) 114 (77.6%)
IV 0 1 (0.7%)
Concurrent chemotherapy, # (%)
Yes 103 (81.7%) 121 (82.3%)
Radiation technique, # (%)
3DCRT 122 (96.8%) 143 (97.3%)
IMRT 4 (3.2%) 4 (2.7%)
IQR, interquartile range.
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We modeled the incidence of grade 3 esophagitis after initiation of
radiotherapy as a function of associations with dose, selected clinical
and dosimetric factors, and pretreatment cytokine levels using
multivariable logistic regression. To account for the low ratio of
number of events to number of covariates, which can negatively
impact precision, we applied “elastic net” penalization to the
regression [56]. The elastic net is equipped to automatically exclude
unimportant variables from the model and shrink the estimated
associations of those that remain. This first characteristic encourages
simplicity and interpretability in the selected model, whereas the
second helps improve the external validity of the model in subsequent
assessments. The number of variables excluded and the degree of
shrinkage are automatically tuned based upon optimizing perfor-
mance in a cross-validated framework, whereby proportions of the
data are sequentially held apart and treated as small validation sets.
Specifically, we maximized the cross-validated log-likelihood, a
statistical measure of the agreement between each patient's
model-predicted risk of grade 3 esophagitis and whether she/he
developed it. We also measured cross-validated area under the
receiver-operating characteristic curve (AUC), a measure of discrim-
inatory ability. We note that standard measures of “statistical
significance” such as P values do not account for the variable
selection or shrinkage process and thus would be potentially
misleading in our analysis. Rather, by definition of being included
in the final model, a covariate is considered to have a meaningful
association with the outcome (grade 3 esophagitis).
To focus on and distinguish between the impacts of associations
corresponding to the set of clinical factors and those corresponding to
the set of pretreatment cytokines, we compared four families of
prediction models for esophagitis, differing in terms of the maximum
possible level of complexity. The simplest model was a baseline
comparison model for predicting grade 3 esophagitis using dosimetric
factors only. We applied our model building approach separately for
two dosimetrics: D2cc and gEUD to the esophagus, with a = 5.
Generalized equivalent uniform dose is a numerical representation of
the estimated biologic effect of dose distributed heterogeneously
throughout a given structure, represented as a single dose distributed
uniformly, and is expressed in units of Gy [57]. The relative
contribution of maximum dose can be differentially weighted by
adjusting the “a” factor. When calculated with an “a” of 1, gEUD is
equivalent to mean dose. Increasing the “a” value leads to greater
weighting of maximum dose even if the volume receiving this dose is
small. High “a” values are appropriate for serial organs, such as the
esophagus and bowel, as the function of such organs can be impaired
by damage to a small volume. Conversely, low “a” values are more
appropriate for parallel organs, such as the liver, as functional
impairment requires damage to a relatively larger volume.
We then added a set of prespecified clinical factors: concurrent
chemotherapy, smoking status (current, former, never), age, sex,
simple stage, and Karnofsky performance status (KPS). Finally, we also
added pretreatment cytokine levels, modeled either as having direct
associations with toxicity or as indirectlymodifying the dose-esophagitis
association. To ensure valid comparability, all models were built and
cross-validated against an identical subcohort of 126 patients with
observed pretreatment cytokine levels but potentially missing dose
levels. These missing values were accounted for using multiple
imputation. Given the number of cytokines, we did not consider an
approach for imputing the missing cytokine values.The statistical shrinkage of the elastic net approach was applied to
each family of models except for the dose-only model. However, in
none of the models was this shrinkage applied to the association
parameter corresponding to dose, as doing so would contradict the
clear underlying biological rationale for a strong association between
dose and esophagitis. All analyses were conducted in R [58,59].
Additional details are given in the Supplement.
Results
We identified 147 patients treated with definitive, fractionated
radiotherapy on the above-described protocols from 2004 to 2013. At
a median follow-up of 3.5 years (range 1.3-10.1), the incidence of
grade 3 esophagitis in this cohort was 10.2% (15/147). There were no
cases of grade 4 or 5 esophagitis. Of these 147 patients, 22 had
missing or corrupted dose information and 21 did not have any
cytokines measured. As described above, patients without cytokine
data were excluded from our model-building cohort, while the
patients with missing dose values were accounted for using multiple
imputation. The incidence of grade 3 esophagitis in the 126 analyzed
patients was 10.3% (13/126), which was similar to that observed in
the full cohort. Characteristics of the full cohort (n = 147) and the
reduced cohort with pretreatment cytokines measured (n = 126) are
reported in Table 1.
Table 2 gives the results from the model fitting procedure against
the 126 patients for both analyzed dosimetrics, namely, D2cc and
Translational Oncology Vol. 11, No. 1, 2018 Prediction of Radiation Esophagitis in NSCLC Hawkins et al. 105gEUD. In these “dose-only” models, the cross-validated
log-likelihood and AUC were, respectively, −37.7 and 0.750 for
D2cc and −37.7 and 0.727 for gEUD. These increased to −37.1 and
0.779, respectively, when the set of clinical covariates was added to
D2cc (dose + clinical). Clinical factors analyzed included concurrent
chemotherapy, former smoking status, current smoking status,
age, sex, simple TNM stage, and KPS. There was a similar
improvement in model fit when using gEUD, with log-likelihood
increasing to −37.2 and the AUC to 0.768. We emphasize that these
metrics are cross-validated and thus adjusted for overfitting. As such,
numerical increases reflect an improvement in model fit and
predictive performance.
Upon adding pretreatment cytokine measurements, either as
having associations with esophagitis directly or as modifying the
dose-esophagitis relationship, predictive performance degraded. For
D2cc, the log-likelihood values from the cytokine models were −37.8
and −37.4, respectively, and the AUCs were 0.758 and 0.773.
For gEUD, the log-likelihood values from the cytokinemodels were −37.6
and −37.5, and the AUCs were 0.749 and 0.729. Comparing the two
approaches to modeling cytokine levels, the better fitting set allowed a
cytokine to adjust the dose-esophagitis association up or down
(a statistical interaction) rather than being itself directly associated
with esophagitis. However, in an overall comparison, none of the
cytokine models could further improve upon a simpler model using
only dose and clinical covariates. Comparing performance across
dosimetrics, D2cc hadmarginally better performance than gEUD in the
dose + clinical model. Figure 1 plots the model-based (cross-validated)
risks of grade 3 RE using the D2cc dosimetric.
Focusing on the dose + clinical models, which had the best
operating characteristics, we next included data from the 21 patients
who were excluded from the model-building process due to missing
pretreatment cytokine data. We report the individual estimated
associations from refitting the selected dose + clinical model to all 147
patients (Table 3). As expected, increasing dose was strongly
associated with increased risk of esophagitis, with odds ratios (ORs)
of 1.094/Gy (D2cc) and 1.096/Gy (gEUD). In addition to dose, two
clinical covariates were selected for the models. First, women had
slightly higher risk than men, with ORs of 1.090 (D2cc) and 1.112
(gEUD). Additionally, with each dosimetric, there was an incremental
decline in the risk of RE with increasing age, with ORs of 0.992/year
(D2cc) and 0.991/year (gEUD).
Discussion
In the work described here, RE models combining dosimetric and
clinical factors showed improved prediction accuracy compared to
that obtained by dose alone, as reflected in higher AUC and log
likelihood values. Incorporating pretreatment plasma levels of 30
cytokines, however, did not improve results. This was true whetherTable 2. Prediction of Grade 3 Esophagitis Based upon 126 Patients with Measured Cytokines
from Four Models Using Increasing Amounts of Clinical and Cytokine Data
Dose = D2cc Dose = gEUD
AUC Log Likelihood AUC Log Likelihood
Dose only 0.750 −37.7 0.727 −37.7
Dose + clinical 0.779 −37.1 0.768 −37.2
Dose + clinical + Cyt0 0.758 −37.8 0.735 −37.6
Dose + clinical + Dose*Cyt0 0.773 −37.4 0.749 −37.5
The model with the largest log-likelihood (in bold) was selected.
Cyt0, pretreatment cytokine levels.cytokine levels were modeled as direct interactions with RE or as
potential modifiers of the dose-RE association. Of the various models
tested, we found theD2cc + clinicalmodel to yield the highest prediction
accuracy, with an AUC of 0.779 and a log likelihood of −37.1.We found
female gender to be associatedwith amild increase in the risk of RE, while
increasing agewas protective.While these results do not support the use of
pretreatment cytokines to predict grade 3 RE, they do demonstrate the
superiority of a multifactorial approach. While many physicians already
consider patient-specific factors when generating treatment plans,
standardized methods for quantifying risk could allow for more robust
individualization of treatment planning, nutritional optimization, or
other prophylactic intervention.
The incidence of grade 3 RE in this cohort was 10.2%, which is
similar to other recent studies [11]. The majority of our patients
received concurrent chemotherapy, which is both consistent with the
standard of care for locally advanced NSCLC and a previously
described risk factor for RE. The majority of patients analyzed in this
work were treated with 3DCRT. Multiple studies have shown that
the use of IMRT is associated with reduced rates of RE, although
others have shown no improvement [14–22]. With increasing
utilization of IMRT for NSCLC, it is possible that the generalizability
of our results may be reduced.
Despite the abundance of dosimetric factors that have been
correlated with RE, no clearly superior parameter has been identified
for standardized implementation. In 2010, a Quantitative Analysis of
Normal Tissue Effects in the Clinic report identified limiting mean
esophageal dose to b34 Gy as the most significant factor for reducing
the risk of grade 3+ RE, a planning goal also recommended in
Radiation Therapy Oncology Group 0617 [11,60]. The dosimetric
variables analyzed here, D2cc and gEUD, were selected due to recent
promising results regarding their use in predicting RE [41]. D2cc is a
parameter often used as surrogate for maximum point dose and is
commonly used in other settings [61,62]. The importance of volume
of esophagus receiving high radiation dose is supported by a large
meta-analysis that identified the volume of esophagus receiving 60 Gy
(V60) as the strongest correlate of RE [30]. As discussed in the
methods section above, gEUD calculated with an “a” value N1
incorporates maximum dose while also accounting for dose to the
entire organ.
We note that the finding that increasing age correlated with lower
risk of RE is consistent with our previous report focusing specifically
on this phenomenon [63] but that the magnitude of the association is
smaller here. This was likely due to multiple factors, including the use
of statistical shrinkage via the elastic net, which was employed in this
study to reduce false-positive findings given the high number of
model-building parameters and which forces all estimated associations
to be smaller; the inclusion of the additional clinical covariate of sex;
and the inclusion of an additional 22 patients in this study with
missing dose information. That the association between age and RE
was similar despite these differences supports the findings in the
previous study.
There are several potential reasons why our analysis failed to show a
correlation between pretreatment plasma cytokine levels and grade 3
RE. One possibility is that an inadequate number of cytokines was
investigated and that some cytokine that was not measured could
correlate with RE. However, this is unlikely given the volume and
diversity of the panel, as well as the interrelatedness of cytokine
expression patterns and functions. We investigated a broad panel of
cytokines, including many of those linked to esophagitis of other
Figure 1. Predicted risk of grade 3 RE by various D2cc-based prediction models. Green and purple dots represent patients who did not
and did develop grade 3 RE, respectively.
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those in which SNPs have been shown to correlate with RE, and those
induced by radiation in mouse models [43,44,46–49,51]. Another
possibility is that cytokines may have been lost or degraded during
isolation or storage, as they are labile in plasma. However, our group
has successfully collected and analyzed plasma cytokine levels in
multiple previous studies [64–66], with these samples having been
handled similarly.
While we analyzed pretreatment cytokine levels in this work, it is
possible that cytokine data obtained mid- or following treatment
could distinguish patients with and without RE. Such a phenomenon
has been observed in lung toxicity, with both pretreatment and
treatment-induced cytokine levels having been shown to correlate
with risk of RILT (reviewed in [51]). However, as RE often develops
within the first several weeks of radiotherapy, as opposed to radiation
pneumonitis and pulmonary fibrosis, which generally develop
months after treatment, such information would be inherently less
able to direct meaningful adaptation of radiotherapy. While our
analysis of plasma cytokines was negative, this alone is a significant
finding, as little information regarding cytokines and RE exists in the
published literature.
While the work presented here represents progress in RE
prediction, continued efforts to improve accuracy are warranted.
Several areas are promising, including incorporation of cross-sectional
and functional imaging. For example, midtreatment esophageal
expansion on CT and increased esophageal fludeoxyglucose avidity
on PET have been correlated with RE [67–69]. However, as these are
midtreatment findings, their ability to guide treatment optimization
may be limited. In addition, other, noncytokine biologic factors haveTable 3. ORs for Dosimetric and Clinical Factors from Selected “Dose + Clinical” Multivariable
Models of Grade 3 RE in Cohort of 147 Patients (21 Additional Patients Who Were Missing
Cytokine Measurements Were Readded into the Analysis Cohort after Model Selection)
Dose = D2cc Dose = gEUD
Dose (OR per Gy) 1.094 1.096
Female sex 1.090 1.112
Age (OR per year) 0.992 0.991shown potential for predicting RE, including micro-RNAs (miR-
NAs). In one study, Xu et al. showed elevation of midtreatment
serum levels of certain miRNA species to be associated with RE [70].
However, that study failed to show a correlation between
pretreatment miRNA levels and RE, which, again, could limit
applicability. Certain miRNA-related SNPs have also been linked
with an increased risk of RE [71] and could represent an avenue to
predict risk prior to initiation of treatment.
Conclusions
In this analysis, prediction of grade 3 RE based on dosimetric and clinical
factors was superior to prediction by dosimetry alone. We did not find
evidence that variation in pretreatment plasma cytokine levels further
improved performance, which represents a novel finding. These results
demonstrate the utility of multivariable modeling for predicting RE.
Identification of additional clinical, biologic, imaging, or other factors could
further improve prediction, possibly leading tomore personalized treatment
planning with associated reduced toxicity and improved outcomes.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.tranon.2017.11.005.
References
[1] Auperin A, Le Pechoux C, and Rolland E, et al (2010). Meta-analysis
of concomitant versus sequential radiochemotherapy in locally advanced non–
small-cell lung cancer. J Clin Oncol 28, 2181–2190.
[2] Curran Jr WJ, Paulus R, and Langer CJ, et al (2011). Sequential vs. concurrent
chemoradiation for stage III non–small cell lung cancer: randomized phase III
trial RTOG 9410. J Natl Cancer Inst 103, 1452–1460.
[3] Werner-Wasik M, Paulus R, and Curran Jr WJ, et al (2011). Acute esophagitis
and late lung toxicity in concurrent chemoradiotherapy trials in patients with
locally advanced non–small-cell lung cancer: analysis of the Radiation Therapy
Oncology Group (RTOG) database. Clin Lung Cancer 12, 245–251.
[4] Trotti A, Colevas AD, and Setser A, et al (2003). CTCAE v3.0: development of a
comprehensive grading system for the adverse effects of cancer treatment. Semin
Radiat Oncol 13, 176–181.
[5] Cox JD, Pajak TF, and Asbell S, et al (1993). Interruptions of high-dose radiation
therapy decrease long-term survival of favorable patients with unresectable non–small
cell carcinoma of the lung: analysis of 1244 cases from3RadiationTherapyOncology
Group (RTOG) trials. Int J Radiat Oncol Biol Phys 27, 493–498.
Translational Oncology Vol. 11, No. 1, 2018 Prediction of Radiation Esophagitis in NSCLC Hawkins et al. 107[6] Choy H, LaPorte K, and Knill-Selby E, et al (1999). Esophagitis in combined
modality therapy for locally advanced non–small cell lung cancer. Semin Radiat
Oncol 9, 90–96.
[7] Antonadou D, Coliarakis N, and Synodinou M, et al (2001). Randomized phase
III trial of radiation treatment +/− amifostine in patients with advanced-stage
lung cancer. Int J Radiat Oncol Biol Phys 51, 915–922.
[8] Maguire PD, Sibley GS, and Zhou SM, et al (1999). Clinical and dosimetric
predictors of radiation-induced esophageal toxicity. Int J Radiat Oncol Biol Phys
45, 97–103.
[9] Ahn SJ, Kahn D, and Zhou S, et al (2005). Dosimetric and clinical predictors for
radiation-induced esophageal injury. Int J Radiat Oncol Biol Phys 61, 335–347.
[10] Patel AB, Edelman MJ, and Kwok Y, et al (2004). Predictors of acute esophagitis
in patients with non–small-cell lung carcinoma treated with concurrent
chemotherapy and hyperfractionated radiotherapy followed by surgery. Int J
Radiat Oncol Biol Phys 60, 1106–1112.
[11] Bradley JD, Paulus R, and Komaki R, et al (2015). Standard-dose versus
high-dose conformal radiotherapy with concurrent and consolidation carboplatin
plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB
non–small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial
phase 3 study. Lancet Oncol 16, 187–199.
[12] Ren XC, Wang QY, and Zhang R, et al (2016). Accelerated hypofractionated
three-dimensional conformal radiation therapy (3 Gy/fraction) combined with
concurrent chemotherapy for patients with unresectable stage III non–small cell
lung cancer: preliminary results of an early terminated phase II trial. BMC Cancer
16, 288.
[13] Zehentmayr F, Sohn M, and Exeli AK, et al (2015). Normal tissue complication
models for clinically relevant acute esophagitis (N/= grade 2) in patients treated
with dose differentiated accelerated radiotherapy (DART-bid). Radiat Oncol 10,
121.
[14] Gomez DR, Tucker SL, and Martel MK, et al (2012). Predictors of high-grade
esophagitis after definitive three-dimensional conformal therapy,
intensity-modulated radiation therapy, or proton beam therapy for non–small
cell lung cancer. Int J Radiat Oncol Biol Phys 84, 1010–1016.
[15] Chun SG, Hu C, and Choy H, et al (2017). Impact of intensity-modulated
radiation therapy technique for locally advanced non–small-cell lung cancer: a
secondary analysis of the NRG Oncology RTOG 0617 randomized clinical trial.
J Clin Oncol 35, 56–62.
[16] Grills IS, Yan D, and Martinez AA, et al (2003). Potential for reduced toxicity
and dose escalation in the treatment of inoperable non–small-cell lung cancer: a
comparison of intensity-modulated radiation therapy (IMRT), 3D conformal
radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys 57,
875–890.
[17] Sura S, Gupta V, and Yorke E, et al (2008). Intensity-modulated radiation
therapy (IMRT) for inoperable non–small cell lung cancer: the Memorial
Sloan-Kettering Cancer Center (MSKCC) experience. Radiother Oncol 87,
17–23.
[18] Shirvani SM, Jiang J, and Gomez DR, et al (2013). Intensity modulated
radiotherapy for stage III non–small cell lung cancer in the United States:
predictors of use and association with toxicities. Lung Cancer 82, 252–259.
[19] Ling DC, Hess CB, and Chen AM, et al (2016). Comparison of toxicity between
intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy for
locally advanced non–small-cell lung cancer. Clin Lung Cancer 17, 18–23.
[20] Murshed H, Liu HH, and Liao Z, et al (2004). Dose and volume reduction for
normal lung using intensity-modulated radiotherapy for advanced-stage non–
small-cell lung cancer. Int J Radiat Oncol Biol Phys 58, 1258–1267.
[21] Al-Halabi H, Paetzold P, and Sharp GC, et al (2015). A contralateral
esophagus-sparing technique to limit severe esophagitis associated with
concurrent high-dose radiation and chemotherapy in patients with thoracic
malignancies. Int J Radiat Oncol Biol Phys 92, 803–810.
[22] Niedzielski J, Bluett JB, and Williamson RT, et al (2013). Analysis of
esophageal-sparing treatment plans for patients with high-grade esophagitis. J
Appl Clin Med Phys 14, 4248.
[23] Werner-Wasik M, Pequignot E, and Leeper D, et al (2000). Predictors of severe
esophagitis include use of concurrent chemotherapy, but not the length of
irradiated esophagus: a multivariate analysis of patients with lung cancer treated
with nonoperative therapy. Int J Radiat Oncol Biol Phys 48, 689–696.
[24] Singh AK, Lockett MA, and Bradley JD (2003). Predictors of radiation-induced
esophageal toxicity in patients with non–small-cell lung cancer treated with
three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 55,
337–341.[25] Bradley J, Deasy JO, and Bentzen S, et al (2004). Dosimetric correlates for acute
esophagitis in patients treated with radiotherapy for lung carcinoma. Int J Radiat
Oncol Biol Phys 58, 1106–1113.
[26] Belderbos J, Heemsbergen W, and Hoogeman M, et al (2005). Acute esophageal
toxicity in non–small cell lung cancer patients after high dose conformal
radiotherapy. Radiother Oncol 75, 157–164.
[27] Chapet O, Kong FM, and Lee JS, et al (2005). Normal tissue complication
probability modeling for acute esophagitis in patients treated with conformal
radiation therapy for non–small cell lung cancer. Radiother Oncol 77, 176–181.
[28] Qiao WB, Zhao YH, and Zhao YB, et al (2005). Clinical and dosimetric factors
of radiation-induced esophageal injury: radiation-induced esophageal toxicity.
World J Gastroenterol 11, 2626–2629.
[29] Rodriguez N, Algara M, and Foro P, et al (2009). Predictors of acute esophagitis
in lung cancer patients treated with concurrent three-dimensional conformal
radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys 73, 810–817.
[30] Palma DA, Senan S, and Oberije C, et al (2013). Predicting esophagitis after
chemoradiation therapy for non–small cell lung cancer: an individual patient data
meta-analysis. Int J Radiat Oncol Biol Phys 87, 690–696.
[31] Wei X, Liu HH, and Tucker SL, et al (2006). Risk factors for acute esophagitis in
non–small-cell lung cancer patients treated with concurrent chemotherapy and
three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 66,
100–107.
[32] Kim TH, Cho KH, and Pyo HR, et al (2005). Dose-volumetric parameters of
acute esophageal toxicity in patients with lung cancer treated with
three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 62,
995–1002.
[33] Rosenman JG, Halle JS, and Socinski MA, et al (2002). High-dose conformal
radiotherapy for treatment of stage IIIA/IIIB non–small-cell lung cancer:
technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys 54,
348–356.
[34] Takeda K, Nemoto K, and Saito H, et al (2005). Dosimetric correlations of acute
esophagitis in lung cancer patients treated with radiotherapy. Int J Radiat Oncol
Biol Phys 62, 626–629.
[35] Takeda K, Nemoto K, and Saito H, et al (2006). Predictive factors for acute
esophageal toxicity in thoracic radiotherapy. Tohoku J Exp Med 208, 299–306.
[36] Hirota S, Tsujino K, and Endo M, et al (2001). Dosimetric predictors of
radiation esophagitis in patients treated for non–small-cell lung cancer with
carboplatin/paclitaxel/radiotherapy. Int J Radiat Oncol Biol Phys 51, 291–295.
[37] Langer CJ, Movsas B, and Hudes R, et al (1997). Induction paclitaxel and
carboplatin followed by concurrent chemoradiotherapy in patients with
unresectable, locally advanced non–small cell lung carcinoma: report of Fox
Chase Cancer Center study 94–001. Semin Oncol 24 [S12-89-S12-95].
[38] Huang EX, Bradley JD, and El Naqa I, et al (2012). Modeling the risk of
radiation-induced acute esophagitis for combined Washington University and
RTOG trial 93-11 lung cancer patients. Int J Radiat Oncol Biol Phys 82,
1674–1679.
[39] Landau DB, Hughes L, and Baker A, et al (2016). IDEAL-CRT: a phase 1/2 trial
of isotoxic dose-escalated radiation therapy and concurrent chemotherapy in
patients with stage II/III non–small cell lung cancer. Int J Radiat Oncol Biol Phys
95, 1367–1377.
[40] Kahn D, Zhou S, and Ahn SJ, et al (2005). "Anatomically-correct" dosimetric
parameters may be better predictors for esophageal toxicity than are traditional
CT-based metrics. Int J Radiat Oncol Biol Phys 62, 645–651.
[41] Paximadis P, Schipper M, and Matuszak M, et al (2017). Dosimetric predictors
for acute esophagitis during radiation therapy for lung cancer— results of a large
statewide observational study. Pract Radiat Oncol .
[42] Lackie JM (2010). A dictionary of biomedicine. Oxford: Oxford University
Press; 2010.
[43] Souza RF, Huo X, and Mittal V, et al (2009). Gastroesophageal reflux might
cause esophagitis through a cytokine-mediated mechanism rather than caustic
acid injury. Gastroenterology 137, 1776–1784.
[44] Blanchard C, Stucke EM, and Rodriguez-Jimenez B, et al (2011). A striking local
esophageal cytokine expression profile in eosinophilic esophagitis. J Allergy Clin
Immunol 127, 208–217 [217 e201–207].
[45] Dunbar KB, Agoston AT, and Odze RD, et al (2016). Association of acute
gastroesophageal reflux disease with esophageal histologic changes. JAMA 315,
2104–2112.
[46] Hildebrandt MA, Komaki R, and Liao Z, et al (2010). Genetic variants in
inflammation-related genes are associated with radiation-induced toxicity
following treatment for non–small cell lung cancer. PLoS One 5e12402.
108 Prediction of Radiation Esophagitis in NSCLC Hawkins et al. Translational Oncology Vol. 11, No. 1, 2018[47] Guerra JL, Gomez D, and Wei Q, et al (2012). Association between single
nucleotide polymorphisms of the transforming growth factor beta1 gene and the
risk of severe radiation esophagitis in patients with lung cancer. Radiother Oncol
105, 299–304.
[48] Zhang L, Yang M, and Bi N, et al (2010). Association of TGF-beta1 and XPD
polymorphisms with severe acute radiation-induced esophageal toxicity in locally
advanced lung cancer patients treated with radiotherapy. Radiother Oncol 97, 19–25.
[49] Epperly MW, Gretton JA, and DeFilippi SJ, et al (2001). Modulation of
radiation-induced cytokine elevation associated with esophagitis and esophageal
stricture by manganese superoxide dismutase-plasmid/liposome (SOD2-PL) gene
therapy. Radiat Res 155, 2–14.
[50] Epperly MW, Guo HL, and Jefferson M, et al (2003). Cell phenotype specific
kinetics of expression of intratracheally injected manganese superoxide
dismutase-plasmid/liposomes (MnSOD-PL) during lung radioprotective gene
therapy. Gene Ther 10, 163–171.
[51] Kong FM and Wang S (2015). Nondosimetric risk factors for radiation-induced
lung toxicity. Semin Radiat Oncol 25, 100–109.
[52] Hart JP, Broadwater G, and Rabbani Z, et al (2005). Cytokine profiling for
prediction of symptomatic radiation-induced lung injury. Int J Radiat Oncol Biol
Phys 63, 1448–1454.
[53] Stenmark MH, Cai XW, and Shedden K, et al (2012). Combining physical and
biologic parameters to predict radiation-induced lung toxicity in patients with
non–small-cell lung cancer treated with definitive radiation therapy. Int J Radiat
Oncol Biol Phys 84, e217–222.
[54] Kong FM, Ten Haken RK, and Schipper MJ, et al (2005). High-dose radiation
improved local tumor control and overall survival in patients with inopera-
ble/unresectable non–small-cell lung cancer: long-term results of a radiation dose
escalation study. Int J Radiat Oncol Biol Phys 63, 324–333.
[55] Zhao L, Wang L, and Ji W, et al (2009). Elevation of plasma TGF-beta1 during
radiation therapy predicts radiation-induced lung toxicity in patients with non–
small-cell lung cancer: a combined analysis from Beijing and Michigan. Int J
Radiat Oncol Biol Phys 74, 1385–1390.
[56] Zou H and Hastie T (2005). Regularization and variable selection via the elastic
net (vol B 67, pg 301, 2005). J Roy Stat Soc B 67, 768.
[57] Liu F, Yorke ED, and Belderbos JS, et al (2013). Using generalized equivalent
uniform dose atlases to combine and analyze prospective dosimetric and radiation
pneumonitis data from 2 non–small cell lung cancer dose escalation protocols. Int
J Radiat Oncol Biol Phys 85, 182–189.
[58] Wickham H (2009). Ggplot2 : elegant graphics for data analysis. New York:
Springer; 2009.[59] Team RC (2016). R: a language and environment for statistical computing.
Vienna, Austria: R Foundation for Statistical Computing; 2016. Available at
https://www.R-project.org, Accessed date: 16 November 2016.
[60] Werner-Wasik M, Yorke E, and Deasy J, et al (2010). Radiation dose-volume
effects in the esophagus. Int J Radiat Oncol Biol Phys 76, S86–93.
[61] Georg P, Lang S, and Dimopoulos JC, et al (2011). Dose-volume histogram
parameters and late side effects in magnetic resonance image-guided adaptive
cervical cancer brachytherapy. Int J Radiat Oncol Biol Phys 79, 356–362.
[62] Potter R, Haie-Meder C, and Van Limbergen E, et al (2006). Recommendations
from gynaecological (GYN) GEC ESTRO working group (II): concepts and
terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D
dose volume parameters and aspects of 3D image-based anatomy, radiation
physics, radiobiology. Radiother Oncol 78, 67–77.
[63] Soni PD, Boonstra PS, and Schipper MJ, et al (2017). Lower incidence of
esophagitis in the elderly undergoing definitive radiation therapy for lung cancer.
J Thorac Oncol 12, 539–546.
[64] Kong F, Jirtle RL, and Huang DH, et al (1999). Plasma transforming growth
factor-beta1 level before radiotherapy correlates with long term outcome of
patients with lung carcinoma. Cancer 86, 1712–1719.
[65] Anscher MS, Kong FM, and Andrews K, et al (1998). Plasma transforming
growth factor beta1 as a predictor of radiation pneumonitis. Int J Radiat Oncol
Biol Phys 41, 1029–1035.
[66] Anscher MS, Kong FM, and Marks LB, et al (1997). Changes in plasma
transforming growth factor beta during radiotherapy and the risk of symptomatic
radiation-induced pneumonitis. Int J Radiat Oncol Biol Phys 37, 253–258.
[67] Mehmood Q, Sun A, and Becker N, et al (2016). Predicting radiation esophagitis
using 18F-FDG PET during chemoradiotherapy for locally advanced non–small
cell lung cancer. J Thorac Oncol 11, 213–221.
[68] Niedzielski JS, Yang J, and Liao Z, et al (2016). (18)F-Fluorodeoxyglucose
positron emission tomography can quantify and predict esophageal injury during
radiation therapy. Int J Radiat Oncol Biol Phys 96, 670–678.
[69] Niedzielski JS, Yang J, and Stingo F, et al (2016). Objectively quantifying
radiation esophagitis with novel computed tomography-based metrics. Int J
Radiat Oncol Biol Phys 94, 385–393.
[70] Xu T, Liao Z, and O'Reilly MS, et al (2014). Serum inflammatory miRNAs
predict radiation esophagitis in patients receiving definitive radiochemotherapy
for non–small cell lung cancer. Radiother Oncol 113, 379–384.
[71] Li R, Pu X, and Chang JY, et al (2016). MiRNA-related genetic variations
associated with radiotherapy-induced toxicities in patients with locally advanced
non–small cell lung cancer. PLoS One 11e0150467.
